



EXECUTIVE SUMMARY | Q1 2020

Pain Relief Innovation

South Rampart Pharma, LLC (SRP) is a life science preclinical company that is committed to improving the lives of people suffering from acute, chronic or neuropathic pain by developing a new class of non-opioid pain medicines.

FAST FACTS

Headquarters: New Orleans, LA

Company Contact Details:

w: southrampartpharma.com

e: info@southrampartpharma.com

Leadership Team:

» **Hernan A. Bazan MD, FACS**
CEO & Co-Founder

» **Nicolas G. Bazan MD, PhD**
Scientific Co-Founder

Unmet Need in Non-Toxic and Non-Narcotic Pain Management

There is a large unmet need for new, safe, effective and non-opioid pain medications to treat chronic pain, which affects an estimated

> 50 MILLION AMERICANS

CDC, 2019

The worldwide ApAP market is expected to be around

\$1 BILLION

by 2020

Zion Market Research, 2016

The global market for pain management pharmaceuticals was worth

\$38.9 BILLION

in 2018 and is projected to grow to

\$52.1 BILLION

by 2024

Pain Management Drugs Market, 2019

Current Shortcomings with Chronic or High-Dose Acetaminophen/Paracetamol (ApAP) Use

Liver toxicity

Exacerbation of ApAP by alcohol

Increased susceptibility in infants and elderly to ApAP toxicity

Narrow therapeutic area

Opioid Crisis

Highlights the urgency for a new selective pain-relieving compound with **minimal potential for dependence and addiction**


In 2017, more than **72,000 patients** in the U.S. died due to opioid misuse (CDC, 2019) and in 2019, the opioid crisis cost U.S. economy at least **\$631 billion**

(The Washington Post, 2019)

Technology and Intellectual Property

- SRP is developing a new class of small molecule, non-opioid pain medicines
- SRP's proprietary compounds have been **effective in reducing both pain and fever in preclinical studies without liver and kidney toxicity** that are associated with current common over the counter analgesics
 - In three distinct preclinical models of pain, SRP compounds show similar levels of analgesia (pain relief) to ApAP (Figure)
 - SRP has identified the molecular species, NAPQI, a metabolite of ApAP produced that explains liver toxicity
- SRP proprietary compounds have the potential to provide relief for patients with many types of pain, including **chronic, acute post-operative and neuropathic pain**
 - SRP is working with top medicinal chemists to develop oral and intravenous formulations optimized for each indication

Figure: South Rampart Pharma has developed a number of novel analogs of acetaminophen (ApAP) with comparable analgesia.



South Rampart Pharma's solution is a novel small molecule, introducing a value product that will be low cost and accessible to many patients.

Upcoming Milestones

Pre-IND meeting on its lead compound in **March 2020**

Expected submission of **first IND** by **August 2020**

Planned **Phase 1** trial initiation by **September 2020**